Followers | 104 |
Posts | 2500 |
Boards Moderated | 0 |
Alias Born | 12/02/2016 |
Thursday, September 21, 2017 4:13:26 PM
What I've understood after listening to last week's Parliament hearing, is that South Africa has gone through much of the due process, and is consequently now positioned to reschedule/down-schedule cannabis within the next few weeks.
https://drive.google.com/file/d/0B4WJojoiFSszTVE5UERWdFAxWmc/view
Upon the SA governmental ratification, according to the founder of SACCRA Jason Sean O'Donoghue, Plandai SA/Protext Pharma is expected to "gain access" to a research and development license that will allow for the company to employ its proprietary technology to produce a pharmaceutical grade non-psychoactive cannabis product under license from America. IMO, the implications of South Africa down-scheduling cannabis are profound for $TXTM. It will be interesting to see what unfolds over the next few weeks.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM